Disc Medicine (IRON) Competitors $59.19 +0.60 (+1.02%) As of 01:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRON vs. ROIV, GRFS, LEGN, ELAN, RVMD, RYTM, NUVL, TGTX, AXSM, and LNTHShould you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Nuvalent (NUVL), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Disc Medicine vs. Its Competitors Roivant Sciences Grifols Legend Biotech Elanco Animal Health Revolution Medicines Rhythm Pharmaceuticals Nuvalent TG Therapeutics Axsome Therapeutics Lantheus Disc Medicine (NASDAQ:IRON) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends. Is IRON or ROIV more profitable? Disc Medicine has a net margin of 0.00% compared to Roivant Sciences' net margin of -225.71%. Roivant Sciences' return on equity of -14.76% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -27.75% -25.64% Roivant Sciences -225.71%-14.76%-13.69% Which has stronger valuation and earnings, IRON or ROIV? Disc Medicine has higher earnings, but lower revenue than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$109.36M-$4.47-13.24Roivant Sciences$29.05M269.00-$171.98M-$0.25-45.98 Which has more risk and volatility, IRON or ROIV? Disc Medicine has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Do analysts rate IRON or ROIV? Disc Medicine currently has a consensus price target of $95.73, suggesting a potential upside of 61.73%. Roivant Sciences has a consensus price target of $16.50, suggesting a potential upside of 43.54%. Given Disc Medicine's higher possible upside, research analysts clearly believe Disc Medicine is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the media favor IRON or ROIV? In the previous week, Roivant Sciences had 2 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for Roivant Sciences and 7 mentions for Disc Medicine. Roivant Sciences' average media sentiment score of -0.07 beat Disc Medicine's score of -0.19 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders & institutionals believe in IRON or ROIV? 83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 3.6% of Disc Medicine shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryRoivant Sciences beats Disc Medicine on 10 of the 16 factors compared between the two stocks. Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRON vs. The Competition Export to ExcelMetricDisc MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.05B$3.03B$5.50B$9.81BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-13.2417.3829.9425.16Price / SalesN/A349.44445.68102.78Price / CashN/A40.7324.8128.01Price / Book3.998.988.685.82Net Income-$109.36M-$54.75M$3.26B$265.22M7 Day Performance-2.70%-0.94%0.61%0.75%1 Month Performance4.01%7.33%3.33%1.97%1 Year Performance31.47%23.30%45.75%27.33% Disc Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRONDisc Medicine3.2234 of 5 stars$59.19+1.0%$95.73+61.7%+36.0%$2.05BN/A-13.2430Earnings ReportROIVRoivant Sciences2.0068 of 5 stars$11.51+1.8%$16.50+43.4%+0.4%$7.69B$29.05M-46.04860News CoveragePositive NewsGRFSGrifols3.4508 of 5 stars$10.72-0.6%$10.30-3.9%+47.0%$7.41B$7.81B9.1623,822LEGNLegend Biotech3.8019 of 5 stars$38.45-0.9%$73.33+90.7%-35.2%$7.13B$627.24M-65.172,609Trending NewsEarnings ReportAnalyst ForecastELANElanco Animal Health3.3432 of 5 stars$14.07+2.1%$16.17+14.9%+31.2%$6.85B$4.44B19.029,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionRVMDRevolution Medicines4.3603 of 5 stars$37.18+1.5%$68.91+85.3%-19.1%$6.82B$11.58M-9.30250Earnings ReportAnalyst RevisionRYTMRhythm Pharmaceuticals3.4791 of 5 stars$90.24+2.2%$91.93+1.9%+108.4%$5.62B$130.13M-32.11140Earnings ReportAnalyst RevisionNUVLNuvalent3.1379 of 5 stars$78.35+0.8%$119.60+52.6%+7.1%$5.58BN/A-17.8540Earnings ReportUpcoming EarningsAnalyst RevisionTGTXTG Therapeutics4.1154 of 5 stars$28.72-18.0%$43.80+52.5%+32.5%$5.56B$329M119.67290High Trading VolumeAXSMAxsome Therapeutics4.8038 of 5 stars$106.54+3.4%$172.33+61.8%+25.1%$5.07B$385.69M-18.46380LNTHLantheus4.8368 of 5 stars$71.46+1.3%$131.20+83.6%-42.4%$4.88B$1.53B20.30700Positive NewsEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Roivant Sciences Alternatives Grifols Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Rhythm Pharmaceuticals Alternatives Nuvalent Alternatives TG Therapeutics Alternatives Axsome Therapeutics Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRON) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access